Visual Hallucinations Induced by the Combination of Prolintane and Diphenhydramine

The case of a young man is presented who developed visual hallucinations following two months of concomitant use of prolintane and diphenhydramine at therapeutic dosages. An increase in dopaminergic brain activity is proposed as the causal mechanism for hallucinations - whereas prolintane can induce the release of dopamine at the synaptic cleft, diphenhydramine can act inhibiting the reuptake of dopamine and inducing a potentiation of its effects. The psychiatric complications appearing two months after starting the use of both drugs could be attributed to a phenomenon of pharmacological kindling.

References

• 1 Nicholson A N, Stone B M. Heterocyclic amphetamine derivatives and caffeine on sleep in man.  Br J Clin Pharmacol. 1980;  9 195-203
• 2 Newbold G F. Prolintane in debility and fatigue.  Practitioner. 1974;  1278 868-870
• 3 Martínez-Mir I, Catalan C, Palop V. Prolintane: a “masked” amphetamine.  Ann Pharmacother. 1997;  31 (2) 256
• 4 Shader R I, Greenblatt D J. Belladone alkaloids and synthetic anticholinergics; uses and toxicity. In: Sheder RI (ed) Psychiatric complications of medical drugs. New York; Raven Press 1972: 102-147
• 5 Fuller R W, Snoddy H D. Effects of prolintane on 3,4 dihydroxyphenylacetic acid concentration in rat brain after spiperone treatment.  Pharmacol Biochem Behav. 1979;  10 561-563
• 6 Coyle J T, Snyder S H. Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action.  Science. 1969;  166 899-901
• 7 Moskovitz C, Moses H, Klawans H L. Levodopa-induced psychosis: a kindling phenomenon.  Am J Psychiatry. 1978;  135 669-675